GSN and neoplasm: To evaluate the mechanisms of tumor resistance to TRAIL and the ability of gelsolin to sensitize cells to TRAIL mediated cell death, we investigated human hepatoma (HepG2) and hepatocellular carcinoma (Huh7) cells exhibiting reduced sensitivity to TRAIL19.